Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.53 |
| ▸ | CCND1 | P24385 | 19/20 | 0.53 |
| ▸ | CDK2 | P24941 | 10/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.53 |
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.49 |
| ▸ | CCND2 | P30279 | 12/20 | 0.49 |
| ▸ | CCND3 | P30281 | 12/20 | 0.49 |
| ▸ | CDK1 | P06493 | 5/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188527 | 0.88 | WEE1 (0.44) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL189272 | 0.86 | WEE1 (0.42) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL3337709 | 0.84 | CDK4 (0.59) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL189818 | 0.81 | PIK3CA (0.60) | — | |
| SCHEMBL4218283 | 0.81 | CDK4 (0.54) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL3339292 | 0.80 | CDK4 (0.61) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL4220885 | 0.80 | CDK4 (0.53) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL3339620 | 0.80 | CDK4 (0.55) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL189845 | 0.79 | CDK4 (0.55) | CDK4CCND1CDK2CCNE1CDK6 | |
| SCHEMBL4227763 | 0.78 | CDK4 (0.51) | CDK4CCND1CDK2CCNE1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | claimed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | CDK4 171/4885CCND1 2147/4885CDK2 149/4885 |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | CDK4 265/4885CCND1 805/4885CDK2 112/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | CDK4 171/4885CCND1 2147/4885CDK2 149/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | CDK4 159/4885CCND1 1833/4885CDK2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.